Related Experiment Videos

Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy

N Yuki1, M Yamada, Y Tagawa

  • 1Department of Biochemistry, Faculty of Medicine, Tokyo Medical and Dental University, Japan. yuki@dokkyomed.ac.jp

Insights

Anti-GD2 monoclonal antibody (MAb) treatment for melanoma can cause neurotoxicity. This study found GD2 on peripheral nerve myelin and pituitary cells, explaining the observed sensorimotor neuropathy and SIADH.

Area of Science:

  • Neuroscience
  • Immunology
  • Oncology

Background:

  • Melanoma patients treated with anti-GD2 monoclonal antibody (MAb) can develop neurotoxic side effects.
  • These side effects include sensorimotor demyelinating polyneuropathy and syndrome of inappropriate antidiuretic hormone (SIADH).

Purpose of the Study:

  • To investigate the underlying cause of anti-GD2 MAb-induced neurotoxicity.
  • To determine the localization of GD2 antigen within the human nervous system.

Main Methods:

  • Immunohistochemical analysis of human nervous system tissues.
  • Utilized anti-GD2 MAb (14G2a) for staining.

Main Results:

  • GD2 antigen was localized to the myelin sheaths of peripheral nerves.
  • GD2 was also found in the cytoplasm of pituicytes in the posterior pituitary gland.

Conclusions:

  • The binding of anti-GD2 MAb to peripheral nerve myelin likely causes sensorimotor demyelinating polyneuropathy.
  • Binding to posterior pituitary pituicytes is hypothesized to cause SIADH.

Related Concept Videos